Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists

Keyphrases

• United States 100%
• Rheumatologists 100%
• Arthritis 100%
• Factor Inhibitors 100%
• Necrosis Factor 100%
• Tumour Necrosis Factor Inhibitor (TNFi) 60%
• Rheumatoid Arthritis 40%
• Perceived Barriers 20%
• Tuberculosis 10%
• Response Rate 10%
• Newly Diagnosed 10%
• Methotrexate 10%
• National Sample 10%
• Laboratory Practice 10%
• Laboratory Monitoring 10%
• Insurance Coverage 10%
• Prescribing Practices 10%
• Lack of Response 10%
• Survey Questionnaire 10%
• Rheumatoid Arthritis Patients 10%
• Etanercept 10%
• Infliximab 10%
• Nonresponse Bias 10%
• Non-response 10%
• Practice Barriers 10%
• Moderate Rheumatoid Arthritis 10%
• Purified Protein Derivative 10%
• Adalimumab 10%
• Disease-modifying Antirheumatic Drugs (DMARDs) 10%
• Monitoring Protocol 10%

Nursing and Health Professions

• Rheumatologist 100%
• Arthritis 100%
• Necrosis 100%
• Rheumatoid Arthritis 60%
• Tumor Necrosis Factor Inhibitor 60%
• Inflammatory Arthritis 60%
• Tuberculin 10%
• Side Effect 10%
• Methotrexate 10%
• Nonresponse Bias 10%
• Disease Modifying Antirheumatic Drug 10%
• Adalimumab 10%
• Infliximab 10%
• Etanercept 10%